Skip to content
S10466Senate2025-2026 SessionSame asA6927

Update Prescription Labels for Hormones

Official title

“Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy”

Sponsor Erik BottcherSD-47Affects Education
Status
In Senate Committee
Higher Education
Impact
6/10
Moderate
Passage
34%

Bill progress

Step 2 of 7

In committee · Higher Education

What's happening

This bill allows prescription labels for certain gender dysphoria and hormone drugs to list the clinic instead of the doctor's name.

Why it matters

  1. Expands privacy protections for transgender and gender-diverse individuals statewide. by allowing prescription labels for certain medications used in gender-affirming care to list the clinic’s name instead of the individual prescriber, reducing potential risks of outing or discrimination at pharmacies or at home.

  2. Directly affects patients, prescribers, and pharmacies involved in hormone therapies for gender dysphoria. including youth and adults seeking gender-affirming care—by making it easier and potentially safer to access and store these medications without revealing sensitive provider information.

  3. Requires healthcare providers to notify patients when this labeling option is used. , ensuring transparency and enabling patients to understand how their prescriptions are labeled, which could help them prepare for questions or issues with insurance or pharmacy staff.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Transgender and Gender Non-Conforming Individuals

    People undergoing gender-affirming care who use hormone therapies or puberty blockers would benefit from increased privacy protections on prescription labels.

  • Likely concerns

    Healthcare Providers and Prescribing Practices

    Clinics and providers who prescribe hormone-related medications for gender dysphoria may have concerns about patient confidentiality and staff safety, making this change relevant to their operations and legal compliance.

  • Pharmacists and Pharmacies

    Pharmacists who dispense these medications will need to adjust labeling practices and ensure compliance with the new requirements, impacting their workflow and training.

  • Advocacy and Civil Rights Organizations

    Groups focused on LGBTQ+ rights and medical privacy will be interested in this legislation as it aims to safeguard sensitive patient information and reduce stigma or targeting.

Headline styles

Update Prescription Labels for Hormones

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Erik Bottcher

Senator · Senate District 47

Chair, Cities 1

No co-sponsors yet.

History

  1. Referred to higher education

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A6927Assembly

Protect Privacy on Hormone Labels

In Assembly Committee · Higher Education · Sponsor Tony Simone

Impact 6 · Moderate30% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

10466

IN SENATE

May 15, 2026

Introduced by Sen. BOTTCHER -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education

AN ACT to amend the education law and the public health law, in relation to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Paragraph b-1 of subdivision 1 of section 6807 of the education law, as amended by chapter 108 of the laws of 2025, is amended to read as follows:

b-1. Notwithstanding paragraph b of this [section] subdivision, the prescription label for mifepristone [or], misoprostol, gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria, may include the name or address of the dispensing health care practice instead of the name of the dispenser.

§ 2. Subdivision 1-a of section 6810 of the education law, as amended by chapter 108 of the laws of 2025, is amended to read as follows:

1-a. Notwithstanding subdivision one of this section, at the prescriber's request, the prescription label for mifepristone [or], misoprostol, gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria, shall include the name or address of the prescribing health care practice instead of the name of the prescriber.

§ 3. Section 280-d of the public health law, as added by chapter 108 of the laws of 2025, is amended to read as follows:

§ 280-d. Patient notification of prescription label change. A health care prescriber shall inform the patient if such prescriber has included or has requested to include the name or address of the prescribing health care practice instead of the name of such prescriber on the

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD10852-02-6

prescription label when prescribing mifepristone [or], misoprostol, gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria.

§ 4. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the education law and the public health law, in relation to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treat- ment of gender dysphoria

Purpose

To allow the prescription label for gonadotropin-releasing hormone agon- ists, pubertal suppressants, anabolic steroids, alpha reductase inhibi- tors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria to include the name of a health care prac- tice instead of the name of the prescribing or dispensing practitioner.

Summary of specific provisions

Section 1 would amend paragraph b-1 of subdivision 1 of section 6807 of the education law to allow dispensing practitioners to print the name or address of their practice, rather than their own name, on the prescription label for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria.

Read the full memo (816 words)

Section 2 would amend subdivision 1-a of section 6810 of the education law to allow prescribers to request that the name of their practice, rather than their own name, be printed on the prescription label for on the prescription label to print the name of their practice, rather than their own name, on the prescription label for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reduc- tase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria.

Section 3 would would add a new section 280-d to the public health law to require a healthcare prescriber to notify their patient if they have included or requested to include the name or address of their practice, rather than their own name, on the prescription label for mifepristone, misoprostol, gonadotropin-releasing hormone agonists, pubertal suppres- sants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria.

Section 4 sets the effective date.

Justification

Transgender and gender non-conforming individuals are under attack in the US, with many states and even the federal government moving to restrict gender affirming care for gender non-conforming youth across the country. An executive order recently put into effect rescinds protections for gender affirming care, including urging the Department of Justice to investigate medications prescribed and to prosecute providers, claiming gender affirming care is illegal under laws that prohibit "female genital mutilation." On the state level, the situation is still grim. 26 states have some form of ban on gender affirming care for those under 18. 39.4% or 118,300 trans youth live in a state that bans gender affirming care. Additional states have considered banning gender affirming care for people up to 26 years old, and many states do not allow public funds, such as medicare, to be spent on gender affirm- ing care.

Gender affirming care has a life changing effect on the individuals.

Studies have shown that youth (13-20) who have access to hormone replacement drugs or puberty blockers have 60% lower rates of moderate to severe depression and 73% lower rates of self-harm or suicidal ideol- ogy than those who did not receive these medications. These medications are necessary for the countless gender non-conforming individuals who are struggling in the national mental health crisis, and due to past legislation passed in New York we can help these individuals who need it most.

In 2023, New York passed a telehealth shield law (Chapter 138 of the laws of 2023) to provide broad protection to doctors based in New York serving patients in those states via telehealth. These protections include shielding New York health care practitioners against states that may try to impose criminal sanctions upon them and protection from professional disciplinary action or adverse action from medical malprac- tice insurers. Thanks to New York's shield law, providers based in New York are able to help patients based in hostile states each month, help- ing gender non-conforming individuals who may not otherwise be able to access care.

This bill builds on New York's shield law, by providing further protection to doctors prescribing medications for the treatment of gender dysphoria to patients in hostile states. Modeled after a law recently enacted in New York regarding mifepristone and misoprostol, (Chapter 7 of the Laws of New York, 2025) this bill would allow prescri- bers to request that the dispensing pharmacy include the name of their practice, rather than their name, on the prescription label for gonado- tropin-releasing hormone agonists, pubertal suppressants, anabolic ster- oids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy for treatment of gender dysphoria. Like- wise, dispensing practitioners would be allowed to use the name of their healthcare practice instead of their own name on the label.

Prior legislative history

2025: introduced by then-Senator Hoylman-Sigal

Fiscal implications for state and local governments

None.

Effective date

This act shall take effect immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.